Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.

Pharmacogenetics and genomics - 1 Feb 2017

Gutiérrez-Cívicos Rocío, Hurtado Ana M, Torres-Moreno Daniel, Sanchez-Blanco José J, Español Ignacio, Consuegra-Sánchez Luciano, Perez-Ceballos Elena, Gutiérrez-Meca María D, Jerez Andrés, Conesa-Zamora Pablo

Abstract excerpt

OBJECTIVE: Rituximab in combination with chemotherapy has been proven to increase progression-free and overall survival in follicular lymphoma (FL), but there is considerable interindividual variability in the response. Extrinsic pathway apoptosis triggered by death receptors seems to be involved in the mechanism of action of monoclonal antibodies. This study aimed to assess the association between TRAILR1/TRAIL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fas Ligand Protein

Share to Lymphoma, Follicular

Share to Pharmacogenomic Variants

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Rituximab

Share to Survival Analysis

Source

Identifiers

PMID: 27977511
DOI: 10.1097/FPC.0000000000000262

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.PMID 27977511Read ↗

Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas.Semantic proximity Read ↗

Genetic variations in tumor ecrosis factor related apoptosis-inducing ligand receptor-1 (TRAIL-R1) gene and the susceptibility to b-cell non-hodgkin lymphoma (B-NHL) in Egypt.Semantic proximity Read ↗

A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival.Semantic proximity Read ↗

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.Semantic proximity Read ↗

Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.Semantic proximity Read ↗

Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms.Semantic proximity Read ↗

Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.Semantic proximity Read ↗

FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.Semantic proximity Read ↗

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.Semantic proximity Read ↗

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.Semantic proximity Read ↗

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.